- Home
- CANF vs CINGW Comparison
CANF vs CINGW Comparison
Compare CANF & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- CINGW
- Stock Information
- Founded
- CANF 1994
- CINGW N/A
- Country
- CANF Israel
- CINGW United States
- Employees
- CANF N/A
- CINGW 13
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- CINGW Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- CINGW Health Care
- Exchange
- CANF Nasdaq
- CINGW Nasdaq
- Market Cap
- CANF 7.9M
- CINGW N/A
- IPO Year
- CANF N/A
- CINGW 2021
- Fundamental
- Price
- CANF $1.19
- CINGW $0.04
- Analyst Decision
- CANF Strong Buy
- CINGW
- Analyst Count
- CANF 2
- CINGW 0
- Target Price
- CANF $14.00
- CINGW N/A
- AVG Volume (30 Days)
- CANF 413.8K
- CINGW N/A
- Earning Date
- CANF 04-29-2025
- CINGW N/A
- Dividend Yield
- CANF N/A
- CINGW N/A
- EPS Growth
- CANF N/A
- CINGW N/A
- EPS
- CANF N/A
- CINGW N/A
- Revenue
- CANF $674,000.00
- CINGW N/A
- Revenue This Year
- CANF $461.72
- CINGW N/A
- Revenue Next Year
- CANF N/A
- CINGW N/A
- P/E Ratio
- CANF N/A
- CINGW N/A
- Revenue Growth
- CANF N/A
- CINGW N/A
- 52 Week Low
- CANF $1.22
- CINGW N/A
- 52 Week High
- CANF $4.69
- CINGW N/A
- Technical
- Relative Strength Index (RSI)
- CANF 38.82
- CINGW N/A
- Support Level
- CANF $1.22
- CINGW N/A
- Resistance Level
- CANF $1.27
- CINGW N/A
- Average True Range (ATR)
- CANF 0.13
- CINGW 0.00
- MACD
- CANF -0.02
- CINGW 0.00
- Stochastic Oscillator
- CANF 6.41
- CINGW 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About CINGW Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.